Method and apparatus to support process tool modules in a cleanspace fabricator

Protect your idea by filing a Provisional or Utility Patent Application with the PowerPatent Patent Service. It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.

The Futrfab, Inc. patent solves the following problem:

One known method of advanced technology fabrication materials such as semiconductor substrates, is gathering a manufacturing facility as a cleanroom. In these cleanrooms, processing device arranged to give way to space for human operators or automation equipment. Exemplary cleanroom design described in: Cleanroom Design, Second Edition, edited by W. white, published by John Wiley & sons, 1999, ISBN 0-471-94204-9, (here after referred to as white text) .

Our analysis of this patent is as follows:

Futrfab, Inc.’s patent US 9457442 B2 deals with Method and apparatus to support process tool modules in a cleanspace fabricator.
The present invention provides various aspects of support for a processing device a fabrication facility capable of routine placement and replacement processing tools and component assembly tools. Support aspect includes a support structure for component assembly and a quick disconnect flange that holds the line and disconnect the electrical, liquid and gas utilities to a component of the device over the processing device.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Optical energy-based methods and apparatus for tissue sealing

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time for Utility, Provisional or Design Patent Creation with PowerPatent software and services.

The Covidien Lp patent solves the following problem:

The present disclosure is directed to tissue sealing and, in particular, systems and methods for sealing tissue using optical energy.

Our analysis of this patent is as follows:

Covidien Lp’s patent US 9456870 B2 deals with Optical energy-based methods and apparatus for tissue sealing.
Optical energy-based methods and tools for sealing vascular tissues involves deforming vascular tissues to bring the different layers of the vascular tissue into contact with each other and illuminating the vascular tissue with a light beam that has at least a portion of the spectrum overlapping the absorption spectrum of the vascular tissue. The apparatus may include two deforming members configured to deform the vascular tissue placed between the deforming members. The apparatus may also include an optical system with a light source configured to generate light, a light distribution element configured to distribute light across the vascular tissue, and a light guide configured to guide the light from the light source to light-element distribution. apparatus may further include a cutting member configured to cut the vascular tissue and to shine the light vascular tissue to seal at least a cut face in the vascular tissue.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Method and system to determine erroneous measurement signals during a test measurement sequence

File for Quick & Easy Patent Protection with PowerPatent.

The Lifescan Scotland Limited patent solves the following problem:

Electrochemical glucose test strips, such as those used in the OneTouch Ultra whole blood testing kit, available from LifeScan, Inc., designed to measure the concentration of glucose in a blood sample from the patient with diabetes. The measure of the glucose will be chosen based on glucose oxidation enzyme glucose oxidase (GO). The reaction can occur in a glucose test strip summarized below in Formula 1 and 2.e Glucose + GO (ox) Gluconic Acid + GO (red) Eq. 1 GO (red) + 2FE (CN) 6 3GO (ox) + 2FE (CN) 6 4EQ. 2

Our analysis of this patent is as follows:

Lifescan Scotland Limited’s patent US 9459232 B2 deals with Method and system to determine erroneous measurement signals during a test measurement sequence.
Various embodiments allow a more accurate electrochemical test strip measuring by their false output signal during a glucose level thus ensuring a much more accurate glucose test systems.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

System, method, and computer program product for input/output buffer modeling

Be the First-to-File and Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Cadence Design Systems, Inc. patent solves the following problem:

Our analysis of this patent is as follows:

Cadence Design Systems, Inc.’s patent US 9460250 B1 deals with System, method, and computer program product for input/output buffer modeling.
The present disclosure relates to a computer-implemented method for transient simulation of an input / output buffer models. methods may include the creation of an input / output buffer data file associated with a first model of an electrical circuit. method may also include determining at least one of a node voltage and a current branches associated with the electrical circuit in use, at least in part, a way latency insertion, the method may further include performing one or more simulations at a second model of an electrical circuit, one or more superstitious use, at least in part, the input / output buffer data file and the latency insertion method.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Bis-acylated hydroxylamine derivatives

Protect your idea by filing a Provisional or Utility Patent Application with the PowerPatent Patent Service. It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.

The Cardioxyl Pharmaceuticals, Inc., , The Johns Hopkins University patent solves the following problem:

Our analysis of this patent is as follows:

Cardioxyl Pharmaceuticals, Inc., , The Johns Hopkins University’s patent US 9458127 B2 deals with Bis-acylated hydroxylamine derivatives.
invention provides several bis-acylated hydroxylamine derivative compounds, pharmaceutical compositions and kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions. In particular, the invention provides methods of using such compounds or medicine composition for treating, preventing, or delaying the onset and / or develop a disease or condition. In some embodiments, the disease or condition is selected from cardiovascular disease, ischemia, reperfusion injury, cancerous disease, pulmonary hypertension and the condition responsive to nitroxyl therapy.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Hydrogels for delivery of therapeutic polypeptides

Be the First-to-File and Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The The Board Of Trustees Of The University Of Illinois patent solves the following problem:

Target and local delivery of drugs is a goal of medical and pharmaceutical industries. Target drug delivery aims to optimize drug effective by local therapeutic effect to the sick or infected site or organ of action. A successful therapeutic target provides a significant reduction in drug toxicity, reducing the dose of drug, and increased treatment efficacy as compared to, for example, therapeutics that can specifically target a diseased tissue or organ. Decreased bioavailability of drugs is often a result of their non-specific nature. Furthermore, drug efficacy depends upon the ability of the drug to reach its target in sufficient quantity to maintain therapeutic levels for the desired period of time. Therefore, there is a need for new compositions and methods of local and targeted delivery of therapeutics that is not subject to the same physiological barriers often experienced by, for example, drugs efficaciously not give their therapeutic effects in some target target.

Our analysis of this patent is as follows:

The Board Of Trustees Of The University Of Illinois’s patent US 9457101 B2 deals with Hydrogels for delivery of therapeutic polypeptides.
Expressed here is a hydrogel composition comprising a polymer covalently linked to Glutathione (GSH). also disclosed herein is a method of providing local delivery of one or more agents to a subject suffering from a disease. method comprising administering to the subject a GST / GSH affinity hydrogel containing a therapeutically effective amount of one or more agents.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Methods for producing enteroendocrine cells that make and secrete insulin

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time to make sure it’s protected with a PowerPatent Utility, Provisional or Design Patent Application

The The Trustees Of Columbia University In The City Of New York patent solves the following problem:

Methods for treating and preventing type 1 and 2 diabetes.

Our analysis of this patent is as follows:

The Trustees Of Columbia University In The City Of New York’s patent US 9457079 B2 deals with Methods for producing enteroendocrine cells that make and secrete insulin.
Methods described in enteroendocrine cells and secrete insulin in a mammal by blocking the expression or biological activity of one or more Foxo protein or biologically active fragments or race.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Initial camera mode management system

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time for Utility, Provisional or Design Patent Creation with PowerPatent software and services.

The Gopro, Inc. patent solves the following problem:

It disclosure relates to a system to handle the camera, and more specifically, the detection devices in a system camera, the passing of credentials between the cameras and other devices, and to manage camera operation way.

Our analysis of this patent is as follows:

Gopro, Inc.’s patent US 9462186 B2 deals with Initial camera mode management system.
A camera detects devices, like other cameras, smart devices, and access points, the camera to speak. camera can be different between operating as a wireless station and a wireless access point. camera can connect to and receive credentials from one device to another device that is not connected. In one embodiment, the camera is configured to operate as a wireless access point, and configured to receive credentials from a smart device operates as a wireless station. camera can then transfer the credentials of more cameras, each configured to operate as a wireless station. The camera and additional camera to connect to a Smart device directly or indirectly (eg, through an access point), and the Smart devices can change the way camera to camera. The first step in the camera to be preserved and restored by the Smart device upon disconnection.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Anti-C5a binding moieties with high blocking activity

Apply for Patent – Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Inflarx Gmbh patent solves the following problem:

C5a is cleaved from C5 on complement activation. Among the complement activation products, C5a is one of the most potent inflammatory peptide, with a broad spectrum of functions (Guo and Ward, 2005). C5a is a glycoprotein present in the blood of healthy people with a molecular weight of 11.2 kDa. The polypeptide of C5a contains 74 amino acids, accounting for a molecular weight of 8.2 kDa while the carbohydrate portion causes approximately 3 kDa. C5a exerts its effect through the high-affinity C5a receptor (C5aR and C5L2) (Ward 2009). C5aR belongs to the rhodopsin family of G-protein-coupled receptor with seven transmembrane portion; C5L2 similar but not G-protein-coupled. It is now believed that C5a exerts its biological functions primarily through C5a-C5aR interaction, as in certain biological responses found in C5a-C5L2 interaction. C5aR is widely expressed in myeloid cells including neutrophils, eosinophils, basophils, and monocytes, and nonmyeloid cells in many organs, particularly the lungs and liver, indicating the importance of C5a / C5aR signaling. C5a has a variety of biological functions (Guo and Ward, 2005). C5a is a strong chemoattractant for neutrophil chemotactic activity for monocytes and macrophages. C5a causes an oxidative burst (O2 consumption) in neutrophils and enhances phagocytosis and release granular enzymes. C5a also found a vasodilator. C5a is shown to be involved in the modulation of cytokine expression from different types of cell, to improve the expression of adhesion molecules on neutrophils. It found that C5a can be very harmful when it is more than a disease settings, as it is a strong inducer and enhancer for the inflammatory response-moving stream of inflammatory chain reaction. High doses of C5a lead to nonspecific chemotactic desensitization of neutrophils, thereby causing broad act (Huber-Lang et al. 2001a).

Our analysis of this patent is as follows:

Inflarx Gmbh’s patent US 9458233 B2 deals with Anti-C5a binding moieties with high blocking activity.
The present invention relates to binding moieties that specifically binds to a conformational epitope of C5a, in particular human C5a. Preferred binding moieties of anti-C5a antibodies that bind this conformational epitope. The binding moieties described here are useful as active agents in pharmaceutical compositions for the treatment and prevention of various acute and chronic diseases, in particular acute inflammatory diseases, such as systemic inflammatory response syndrome (SIRS), and different levels of sepsis and sepsis, severe sepsis, and septic shock.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Surgical apparatus and structure for applying sprayable wound treatment material

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time for Utility, Provisional or Design Patent Creation with PowerPatent software and services.

The Covidien Lp patent solves the following problem:

The present disclosure relates to surgical instruments and methods for enhancing properties of tissue repaired or joined the surgical food and, especially in facilities and operations structure configured to use the mechanical surgical fasteners and / or a non- mechanical biocompatible wound treatment material to improve the properties of fixing or adjacent tissue at a target surgical site.

Our analysis of this patent is as follows:

Covidien Lp’s patent US 9456821 B2 deals with Surgical apparatus and structure for applying sprayable wound treatment material.
According to one aspect of the present disclosure, an apparatus for forming an anastomosis between adjacent tissue sections provided. apparatus includes a body portion; an actuation assembly operatively supported at a proximal end of the body; anvil assembly movably mounted on the distal end of the body portion for movement in and out of the body; an estimated congregation came between the body and the anvil assembly for moving the anvil into and out of the tubular body portion; a dispersion assembly operatively associated with the approximation assembly, the dispersion assembly including at least one angled surface defining at least one channel interposed between the anvil assembly and the body portion and configured to dispense a fluid; and at least one conduit for conducting wound treatment material dispersion assembly.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.